Premarket trading brought a mix of earnings-driven moves and analyst-driven downgrades across major sectors, with AstraZeneca leading the declines after a late-stage clinical setback and several consumer and industrial names reacting to quarterly updates.
In early trading, PepsiCo fell after reporting adjusted earnings that slightly missed expectations even as revenue came in above consensus. Salesforce slid following a KeyBanc downgrade, while Stellantis was pressured by another analyst cut tied to the timeline for its turnaround. Levi Strauss dropped on weaker-than-expected third-quarter guidance, while AZZ surged after earnings beat forecasts.
Key takeaways
- AstraZeneca shares fell after the company said its heart disease drug Wainua did not hit a target in a late-stage trial, underscoring clinical risk for investors.
- PepsiCo stock slipped as adjusted second-quarter earnings per share fell short of expectations, despite revenue beating consensus.
- Salesforce declined after a KeyBanc downgrade, reflecting concerns about limited near-term upside signals.
- Levi Strauss fell on disappointing third-quarter guidance even as the company beat prior quarter estimates.
- AZZ rallied after reporting earnings and revenue above analyst forecasts, suggesting improving fundamentals.
Drug and healthcare: AstraZeneca faces late-stage trial setback
AstraZeneca shares dropped 8% in premarket trading after the company said its heart disease drug, Wainua, failed to meet its target in a late-stage clinical trial. The move points to how quickly investors reprice probability of success in late-stage development when efficacy benchmarks are not achieved.
For biopharma investors, the market reaction suggests traders are focused less on near-term financial metrics and more on pipeline risk and the potential downstream impact on future revenue expectations if the program cannot deliver the results needed for regulatory and commercial pathways.
Earnings mix in consumer staples and tech services
PepsiCo shares fell 1% after reporting mixed second-quarter results. The company reported adjusted earnings of $2.20 per share, slightly below the $2.21 consensus estimate from analysts surveyed by LSEG. Revenue came in at $24.18 billion, above the $23.95 billion consensus, indicating that top-line strength did not translate into a meet-or-beat outcome at the earnings line.
In markets, a minor EPS miss can still weigh on sentiment when investors had positioned for a tighter confirmation of earnings momentum. The divergence between revenue and adjusted earnings left investors calibrating how costs, pricing, or mix dynamics flowed through the quarter.
Salesforce was also under pressure, falling 4% following a downgrade by KeyBanc. The firm moved the stock to sector weight from overweight and said it is difficult to identify evidence of future upside based on checks and consumer conversations, along with disclosed company numbers. The decision highlights how research houses evaluate forward demand signals and performance visibility, particularly in software where expectations hinge on durable growth and margin trajectory.
Auto and apparel: analysts question timelines and guidance
Stellantis slid 2% after JPMorgan downgraded the stock to neutral from overweight. Analyst Jose Asumendi said the company needs about 14 months of work to realize benefits from its turnaround efforts. The downgrade suggests the market is increasingly sensitive to execution timelines—when improvements are expected to take longer, the discount rate applied by investors often rises, pressuring shares.
Levi Strauss fell 4% after issuing third-quarter guidance that did not meet analyst expectations. The company projected EPS between 34 cents and 36 cents, below the 38 cents expected by analysts surveyed by FactSet. Even with that guidance miss, Levi Strauss beat second-quarter expectations on both the top and bottom lines, indicating that investors were reacting specifically to forward outlook rather than past performance.
For retailers and apparel names, guidance can be a key driver because it reflects demand visibility, inventory posture, pricing assumptions, and cost management. When management signals a tougher path ahead, the market often prioritizes that change over prior-quarter beats.
Industrials: AZZ jumps after earnings and revenue beat
AZZ rose 6% in premarket trading after reporting earnings per share of $1.85 for the latest quarter, compared with a FactSet consensus estimate of $1.69. Revenue also topped forecasts, reaching $448.5 million versus the $434.6 million forecast.
The reaction suggests investors viewed the results as a confirmation of underlying performance, particularly because the company delivered beats on both the earnings and revenue lines. In premarket, such dual outperformance typically improves confidence in operating momentum and can reduce the risk that analysts’ forward models need to be revised downward.
What to watch next
With several large movers driven by either clinical trial updates or forward-looking commentary, investors will likely focus on follow-through from upcoming results and guidance. Traders will also watch for additional analyst notes that interpret the catalysts—especially AstraZeneca’s late-stage readout, Salesforce’s demand outlook, and the timeline implied by Stellantis’ turnaround—as more earnings and macro data come into view.
